NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the “Offering”) of $50.0 million aggregate principal amount of 8.625% senior unsecured notes due 2030 (the “2030 Notes”). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company’s existing and future wholly-owned domestic restricted subsidiaries and any of its other restricted subs ...

Opaleye Management Inc, a 10% Owner of Harrow (NASDAQ:HROW), reported the indirect sale of 198,572 shares of common stock in multiple open-market transactions on March 3 and March 4, 2026, for a total value of approximately $7.8 million, according to an SEC Form 4 filing. Transaction summary Metric Value Shares sold (indirect) 198,572 Transaction value $7.8 million Post-transaction shares (indirect) 3.7 million Post-transaction value (indirect ownership) $125.1 million Transacti ...

NASHVILLE, Tenn., March 24, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it intends to offer, subject to market and certain other conditions, an additional $50.0 million in aggregate principal amount of its 8.625% senior unsecured notes due 2030 (the "2030 Notes"). The 2030 Notes will be guaranteed on a senior unsecured basis by the Company’s existing and future wholly-owned domestic restricted subsidiari ...

NASHVILLE, Tenn., March 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that three scientific abstracts highlighting its commercial products VEVYE® (cyclosporine ophthalmic solution) 0.1% and ILEVRO® (nepafenac ophthalmic suspension) 0.3% have been accepted for presentation at the American Society of Cataract and Refractive Surgery (ASCRS) 2026 Annual Meeting, taking place April 10–13 at the Walter E. Washing ...

The best opportunity is when the other folks are panicking, but you keep your head. And that time is right. Now.Thanks for reading my research. If you want to learn even more about my research process and what stocks I like, check out my subscription marketplace service Concentrated Value with MVI . You'll get:Harrow, Inc. ( HROW ), is emerging as a dominant player in the US ophthalmic pharmaceuticals space. The company has grown revenue almost 30-fold since it began operations in 2015, led by its ambitious ...

Corporate Presentation Leerink Partners Global Healthcare Conference March 2026 Safe Harbor This presentation contains "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectatio ...

Core Viewpoint - Harrow Inc. reported mixed financial results for the fourth quarter, with earnings per share falling short of expectations while sales exceeded consensus estimates [1][2]. Financial Performance - Fourth quarter earnings were reported at 17 cents per share, missing the consensus estimate of 38 cents [1]. - Sales increased from $66.81 million to $89.09 million, surpassing the consensus estimate of $88.45 million [1]. Research and Development Expenses - Harrow incurred $8.5 million in acquired in-process research and development expenses due to the acquisition of Melt Pharmaceuticals during the fourth quarter and full-year ended December 31, 2025 [2]. Future Sales Expectations - The company anticipates fiscal 2026 sales to be between $350 million and $365 million, which is below the consensus estimate of $386.26 million [2]. Stock Performance - Following the earnings announcement, Harrow shares rose by 3% to $39.76 in pre-market trading [2]. Analyst Ratings and Price Targets - HC Wainwright & Co. analyst Yi Chen maintained a Buy rating on Harrow and raised the price target from $69 to $70 [3]. - Cantor Fitzgerald analyst Steve Seedhouse maintained an Overweight rating but lowered the price target from $94 to $91 [3].

Company Overview - Harrow, Inc. is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products for various eye conditions including dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, and other ocular surface and retina diseases [2] - The company was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes [2] Upcoming Events - Management will present at Leerink Partner's 2026 Global Healthcare Conference on March 10, 2026, at 8:40 AM ET in Miami, Florida [1] - The presentation will be webcast live and available for replay on the company's website for approximately 90 days following the event [1]

Core Viewpoint - The article emphasizes the importance of conducting thorough research and independent verification before making investment decisions, highlighting the inherent risks and volatility associated with stock investments [2][3]. Group 1 - The article provides informational content but does not serve as an exhaustive analysis of any featured company [2]. - It clarifies that the predictions and opinions presented are based on a probabilistic approach rather than absolute certainty [2]. - The author has no financial interest in the companies mentioned, ensuring an unbiased perspective [1]. Group 2 - The article stresses that past performance is not indicative of future results, cautioning readers against relying solely on historical data for investment decisions [3]. - It notes that the views expressed may not reflect those of the platform as a whole, indicating a diversity of opinions among contributors [3]. - The article highlights that analysts may not be licensed or certified, which could affect the reliability of the information provided [3].

Core Viewpoint - Harrow Health (HROW) has garnered investor interest, with a recent "Outperform" rating from William Blair, despite a notable decline in stock price [1][3]. Financial Performance - The Q4 2025 earnings call provided insights into Harrow's financial performance, highlighting achievements and challenges, as well as future outlook [2]. - Harrow Health's market capitalization is approximately $1.43 billion, indicating its size and market presence [4]. Stock Performance - HROW has seen a significant decrease of about 28%, with a drop of $14.99, and the stock price fluctuated between $38.56 and $44.68 during the day [3]. - Over the past year, the stock reached a high of $54.85 and a low of $20.85, reflecting volatility [3]. - The trading volume of 3,933,928 shares indicates active investor interest, which is important for understanding liquidity and growth potential [4].